KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis
Systemic Sclerosis - Diffuse Cutaneous
Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Interventions

BIOLOGICAL: KYV-101
DRUG: Standard lymphodepletion regimen

Sponsor

Kyverna Therapeutics